New clues raise hopes for better treatment of RSV in babies

Article excerpt

Future therapies for respiratory syncytial virus (RSV) must target both the virus and the immune response to ensure babies get the best possible outcomes, a new study by researchers at UCL and Great Ormond Street Hospital for Children (GOSH) finds.